AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) was originally developed as a potential treatment for obesity. It was designed to isolate the fat-burning effects of human growth hormone while removing its anabolic (growth-related) and metabolic side effects.

Research suggests that AOD-9604 may:

• Stimulate lipolysis (breakdown of stored fat)
• Inhibit lipogenesis (formation of new fat cells)
• Act on fat tissue metabolism without significantly affecting blood sugar or IGF-1 levels

Early animal studies showed reductions in body fat and improved fat oxidation, but human clinical trials produced limited and inconsistent weight-loss results, which led to the discontinuation of its development as an approved obesity drug.

Despite ongoing interest in fitness and research communities, AOD-9604 is not FDA-approved, and its safety, purity, and effectiveness can vary widely depending on source. It is generally classified as a research-use-only peptide in most contexts.